◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › A › ABUS

Arbutus Biopharma Corp (ABUS) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · BIOTECHNOLOGY · DATA UPDATED 2026-09-17

Arbutus Biopharma Corp (ABUS) operates in the BIOTECHNOLOGY industry and is headquartered in Warminster, United States with about 19 employees. Its market capitalization is roughly $993 million. In the fiscal year ended 2025-12-31, ABUS reported $14M in revenue and ($34M) in net income.

Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States.

Interactive charts & full statements → Open the ABUS valuation workbench →

ABUS Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Revenue	$182M	$14M	$6M	$18M	$39M	$11M	$7M	$6M	$6M	$11M	$2M	$25M	$15M	$15M	$14M	$16M	$21M	$14M	$10M	$16M	$14M
Gross Profit	$182M	$14M	$6M	$18M	$39M	$11M	($41M)	($52M)	($52M)	($52M)	($60M)	($27M)	($24M)	($6M)	($4M)	($3M)	($1M)	($3M)	($4M)	$16M	$7M
Gross Margin %	100.0%	97.4%	100.0%	100.0%	100.0%	100.0%	-586.7%	-858.3%	-881.4%	-486.0%	-3986.7%	-107.1%	-158.0%	-38.8%	-27.8%	-19.5%	-3.6%	-23.1%	-37.4%	100.0%	54.5%
Operating Income (EBIT)	$147M	($27M)	($76M)	($78M)	($65M)	($74M)	($58M)	($144M)	($90M)	($111M)	($492M)	($102M)	($33M)	($12M)	($13M)	($10M)	($13M)	($9M)	($11M)	$3M	($2M)
Operating Margin %	81.0%	-192.1%	-1236.7%	-430.5%	-167.8%	-669.1%	-836.1%	-2394.0%	-1522.0%	-1036.5%	-32773.3%	-411.4%	-220.0%	-78.6%	-91.6%	-63.3%	-58.6%	-65.8%	-113.6%	16.6%	-12.4%
Net Income	$153M	($34M)	($70M)	($73M)	($69M)	($76M)	($64M)	($154M)	($57M)	($84M)	($384M)	($61M)	($39M)	($14M)	$30M	($10M)	($12M)	($9M)	($12M)	($3M)	$18M
Net Margin %	84.2%	-237.9%	-1133.0%	-401.6%	-178.0%	-693.9%	-922.0%	-2557.4%	-967.8%	-788.8%	-25606.7%	-245.7%	-258.7%	-91.0%	211.2%	-59.7%	-58.1%	-67.7%	-121.6%	-16.2%	132.9%
EBITDA	$153M	($33M)	($68M)	($71M)	($62M)	($72M)	($58M)	($162M)	($59M)	($106M)	($488M)	($77M)	($32M)	($12M)	$34M	($9M)	($11M)	($7M)	($7M)	$3M	$21M
Earnings Per Share (EPS)	$0.78	$-0.17	$-0.38	$-0.44	$-0.46	$-0.72	$-0.84	$-2.69	$-1.03	$-1.54	$-7.24	$-1.34	$-1.73	$-0.92	$2.09	$-0.86	$-1.20	$-0.90	$-1.44	$-0.54	$4.69
Shares Outstanding (M)	197M	192M	186M	166M	151M	106M	76M	57M	55M	55M	53M	45M	22M	15M	14M	11M	10M	10M	8M	5M	4M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ABUS Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Total Revenue	$1M	$179M	$1M	$1M	$11M	$2M	$2M	$1M
Gross Profit	$1M	$179M	$1M	$1M	$11M	($7M)	($7M)	$1M
Gross Margin %	100.0%	100.0%	99.0%	97.9%	100.0%	-407.9%	-459.7%	100.0%
Operating Income (EBIT)	($6M)	$169M	($8M)	($8M)	$1M	($35M)	($14M)	($21M)
Operating Margin %	-588.2%	94.4%	-727.3%	-1567.7%	13.9%	-1964.7%	-885.2%	-1601.2%
Net Income	($5M)	$170M	($4M)	($8M)	$3M	($25M)	($13M)	($20M)
Net Margin %	-507.2%	94.7%	-357.4%	-1463.5%	23.5%	-1390.4%	-796.2%	-1472.5%
EBITDA	($5M)	$170M	($4M)	($8M)	$3M	($24M)	($15M)	($19M)
Earnings Per Share (EPS)	$-0.03	$0.87	$-0.02	$-0.04	$0.01	$-0.13	$-0.07	$-0.10
Shares Outstanding (M)	197M	195M	192M	192M	192M	191M	190M	189M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ABUS Free Cash Flow History

Cash flow	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Cash from Operations (CFO)	($25M)	($40M)	($65M)	($86M)	($35M)	($68M)	($51M)	($71M)	($68M)	($49M)	($58M)	($55M)	($12M)	($7M)	$33M	($8M)	($11M)	($5M)	($8M)	($3M)	($3M)
Capital Expenditures (CapEx)	$14M	$0M	$0M	$1M	$1M	$1M	$0M	$1M	$1M	$7M	$4M	$2M	$1M	$1M	$0M	$0M	$1M	$2M	$1M	$1M	$0M
Free Cash Flow (FCF)	($39M)	($40M)	($65M)	($87M)	($36M)	($68M)	($52M)	($72M)	($69M)	($56M)	($62M)	($57M)	($13M)	($7M)	$33M	($8M)	($12M)	($7M)	($9M)	($4M)	($3M)
FCF Margin %	-21.3%	-281.4%	-1053.8%	-479.3%	-91.9%	-622.0%	-747.3%	-1191.1%	-1170.1%	-522.1%	-4125.4%	-229.5%	-89.8%	-48.3%	234.5%	-46.5%	-56.6%	-49.8%	-98.0%	-25.7%	-20.0%
Dividends Paid	—	—	—	—	—	$12M	$12M	$11M	$10M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ABUS Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Cash from Operations (CFO)	($6M)	($8M)	($5M)	($6M)	($16M)	($13M)	($10M)	($21M)
Capital Expenditures (CapEx)	$6M	$8M	$0M	$0M	$0M	$0M	$0M	$0M
Free Cash Flow (FCF)	($12M)	($16M)	($5M)	($6M)	($16M)	($13M)	($10M)	($21M)
FCF Margin %	-1180.5%	-9.1%	-445.3%	-1099.6%	-146.6%	-759.1%	-660.8%	-1548.6%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ABUS Balance Sheet History

Balance sheet	2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Assets	$274M	$95M	$132M	$144M	$195M	$204M	$137M	$106M	$228M	$237M	$276M	$712M	$118M	$72M	$53M	$14M	$21M	$42M	$42M	$25M	$6M
Cash & Cash Equivalents	$19M	$18M	$36M	$26M	$31M	$109M	$52M	$32M	$37M	$54M	$23M	$167M	$72M	$69M	$47M	$9M	$12M	$23M	$22M	$21M	$5M
Total Liabilities	$15M	$18M	$34M	$38M	$59M	$35M	$35M	$33M	$28M	$55M	$73M	$165M	$30M	$13M	$12M	$8M	$10M	$7M	$4M	$6M	$6M
Total Debt (Short + Long-Term)	$1M	$1M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$18M	$19M	$6M	$1M	$2M	$3M	$0M	$0M	$0M	$3M	$0M	$0M
Total Shareholders' Equity	$259M	$77M	$97M	$106M	$137M	$169M	$102M	$73M	$200M	$182M	$203M	$548M	$88M	$59M	$41M	$5M	$11M	$35M	$38M	$18M	$0M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive ABUS viewer.

Other Companies in BIOTECHNOLOGY

JANX · Janux Therapeutics Inc — $1 billion
ANL · Adlai Nortye Ltd. American Depositary Shares — $1 billion
ATTO · Attovia Therapeutics, Inc. Common Stock — $1 billion
ALMS · Alumis Inc — $1 billion
SGP · SpyGlass Pharma, Inc. — $973 million
SLBT · SL Science Holding Limited Ordinary Shares — $965 million
SLDB · Solid Biosciences LLC — $955 million
SANA · Sana Biotechnology Inc — $928 million

← ABUF All “A” companies ABVC →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.